Catherine Skari

WHO Maintains Official Relations With TIF For 2021-2024

We are very proud to inform you that TIF remains in official relations with the World Health Organization (WHO) for…

Read More »

Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy

The U.S. Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for the experimental gene editing…

Read More »

Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic

The COVID-19 pandemic has had an impact on blood supply in several countries, jeopardizing the already demanding and often suboptimal…

Read More »

EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia

The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) has recently approved EdiGene’s application for ET-01, an…

Read More »

The New Issue of the TIF Newsletter Is Just Released

Read More »

TIF Newsletter – December 2020

Read More »

Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide

Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our…

Read More »

Iranian Blood Transfusion Organization Newsletter – December 2020

The Iranian Blood Transfusion Organization (IBTO) and its most recent activities are featured on TIF’S website.

Read More »

Blood Under The Microscope Of The European Commission: An Article by TIF’s Executive Director

by Dr Androulla Eleftheriou The European Commission published in October 2019 the Evaluation Report of the European legal framework for…

Read More »

THALIA App: The Skilled Digital Assistant of People with Thalassaemia and Sickle Cell Disease

Committed to continuing efforts to develop useful tools for individuals with thalassaemia and haemoglobin disorders worldwide, TIF introduces a novel…

Read More »